A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination with a PARP Inhibitor in Patients with BRCA 1/2 Mutant or Other HRD+ Advanced or Metastatic S

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Brca 1/2 Mutant Or Other Hrd+ Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must have an archival formalin fixed, paraffin embedded (FFPE) tumor sample available that is suitable for NGS or provide a liquid biopsy if archival tissue is not available
    2. Patients must have an existing report (including a prescreening report for this study) from a clinically validated NGS test, documenting mutation(s) in the BRCA1, BRCA2, PALB2, RAD51C, or RAD51D genes or a genome-wide HRD score
    3. Patients must be able to swallow tablets

You may not be eligible for this study if the following are true:

    1. Participation in or has planned participation in a study of another investigational agent or device
    2. Received prior high-dose chemotherapy with bone marrow or stem cell transplant
    3. Myelodysplastic syndrome

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.